Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12607000208404
Ethics application status
Not yet submitted
Date submitted
10/04/2007
Date registered
16/04/2007
Date last updated
16/04/2007
Type of registration
Prospectively registered

Titles & IDs
Public title
Altered breathing with postoperative pain relief
Scientific title
A randomised phase 3/4 study to compare the postoperative effects of morphine versus tramadol/ketamine/parecoxib analgesia on respiratory obstructions, apnoeas and oxygen desaturation.
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Obesity 1733 0
Respiratory Depression 1734 0
Postoperative analgesia 1735 0
Condition category
Condition code
Diet and Nutrition 1825 1825 0 0
Obesity
Respiratory 1826 1826 0 0
Pain management

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
A comparison of morphine with a combination of parecoxib, ketamine and tramadol for analgesia in the first 12 hours after surgery. The tramadol to be given by patient-controlled intravenous doses. Continuous recording of respiratory data for 12-18 hours after surgery in all patients.
Doses: tramadol 3mg/kg + 10mg bolus with 10min lockout, ketamine 0.3mg/kg iv + 0.1mg/kg/hr, parecoxib 40mg iv single dose.
Intervention code [1] 1692 0
Prevention
Comparator / control treatment
Morphine analgesia in the first 12 hours after surgery. The morpine is given by patient-controlled intravenous doses. Continuous recording of respiratory data for 12-18 hours after surgery in all patients.Doses: morphine 1mg bolus with 5min lockout,
Control group
Active

Outcomes
Primary outcome [1] 2558 0
Reduced number respiratory obstructions or desaturations.
Timepoint [1] 2558 0
Total for 12 hours to 0600hr on day after surgery.
Secondary outcome [1] 4404 0
Analgesia and side-effects
Timepoint [1] 4404 0
Average of verbal numeric pain scores for 12hr period to 0600hr, need for rescue analgesia.

Eligibility
Key inclusion criteria
Obese (BMI>29) patients or airway abnormality on preoperative anaesthesia examination.Likely to require postoperative morphine or equivalent analgesia.Postoperative overnight hospital stay.
Minimum age
18 Years
Maximum age
90 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Intrathoracic or upper-abdominal surgery. Previous adverse reaction to any study drugs including nausea or vomiting.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
computer generated table
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Respiratory monitor 12hr recording analysed by researcher blinded to treatment group.
Phase
Phase 3 / Phase 4
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/06/2007
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
70
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 1976 0
Hospital
Name [1] 1976 0
Department of Anaesthesia and Pain Management, RMH
Country [1] 1976 0
Australia
Primary sponsor type
Hospital
Name
Royal Melbourne Hospital
Address
Country
Australia
Secondary sponsor category [1] 1789 0
None
Name [1] 1789 0
Nil
Address [1] 1789 0
Country [1] 1789 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 3672 0
Melbourne Health Research and Ethics Committee
Ethics committee address [1] 3672 0
Ethics committee country [1] 3672 0
Australia
Date submitted for ethics approval [1] 3672 0
Approval date [1] 3672 0
Ethics approval number [1] 3672 0

Summary
Brief summary
Many patients experience some degree of breathing difficulty after major surgery and breathing difficulties may be the basis for serious, but uncommon complications of anaesthesia and surgery. The use of sedatives and morphine-like drugs for the relief of pain, although very necessary, contributes to decreased breathing effort, pauses and obstruction. Patients with obstructive sleep apnoea (OSA) syndrome, associated with a history of snoring, observed pauses in breathing during sleep and daytime sleepiness, may be at especially high risk with anaesthesia. This syndrome is associated with obesity, and may be a partial cause for, many types of heart and lung disease. Specialized high-dependency postoperative care is advocated for these patients.
We are interested in patients who do not have a definite diagnosis of OSA or severe symptoms, but who do have a high body mass index (BMI) and some abnormal airway features that imply increased risk of obstruction. Such patients may make up to 20% of patients presenting for elective surgery at the RMH. An initial respiratory monitoring study in progress, suggests that patients with these risk factors have increased breathing difficulties and reduced blood oxygen in the period after surgery.
In the proposed study, patients who are considered to be at risk of breathing problems on the basis of questionnaires and examination prior to surgery, will be randomized to either standard opioid (morphine) pain relief for the first day after surgery or to a group where other pain relieving dugs (ketamine, parecoxib and tramadol) are used in an attempt to reduce opioid use while maintaining adequate pain relief. In both groups dugs will be used according to protocols approved by the Acute Pain Service at the Royal Melbourne Hospital.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 27795 0
Address 27795 0
Country 27795 0
Phone 27795 0
Fax 27795 0
Email 27795 0
Contact person for public queries
Name 10881 0
A/Prof Duncan Blake
Address 10881 0
Department of Anaesthesia and Pain Management
Royal Melbourne Hospital
Parkville VIC 3050
Country 10881 0
Australia
Phone 10881 0
+61 3 93427925
Fax 10881 0
Email 10881 0
[email protected]
Contact person for scientific queries
Name 1809 0
A/Prof Duncan Blake
Address 1809 0
Department of Anaesthesia and Pain Management
Royal Melbourne Hospital
Parkville VIC 3050
Country 1809 0
Australia
Phone 1809 0
+61 3 93427925
Fax 1809 0
Email 1809 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.